Clin2
NCT07290244Possibly a fitRecruiting

Testing ER-100 safety for glaucoma or NAION patients

Open Angle Glaucoma (OAG)NAION( Non-arteritic Anterior Ischemic Optic Neuropathy)

Part of Brain & nervous system, Eyes & vision clinical trials.

This trial tests whether a new drug, ER-100, is safe for people with glaucoma or a sudden optic nerve injury called NAION. It aims to see if the drug can be given without serious side effects.

Summary written for real people, not researchers, by Clin2.

Phase
Phase 1
Enrollment
18 people
Ages
40 years to 85 years
Study type
Interventional

Who can take part

  • You must be between 40 and 85 years old.
  • You must have clear eye structures and be able to have your pupils dilated for a thorough eye exam.
  • If you have glaucoma: you must have open-angle glaucoma with moderate to advanced vision loss and eye pressure below 30 mmHg.
  • If you have NAION: you must have had sudden, painless vision loss in one eye within the last 14 days, with optic nerve swelling and vision loss confirmed by tests.
  • You must not have certain other eye conditions like severe cataracts, macular problems, or a history of optic neuritis.
  • You must not have had eye surgery within the last 3 months, or have uncontrolled diabetes or a weakened immune system.

View the official record on ClinicalTrials.gov

Quick eligibility check

Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.

Similar studies

Other trials that look related to this one.

NCT07847073Recruiting· Phase 4
Comparing eye drops for glaucoma and their effect on the optic nerve

This trial tests two eye drops—Rhopressa (netarsudil) and timolol—at lowering eye pressure in people with open-angle glaucoma. The study uses a special camera to see if treatment helps protect the nerve cells in the back of the eye.

Bloomington, Indiana
NCT07453888Recruiting· Phase 3
Nose spray for sudden vision loss from optic nerve damage

This trial tests a nose spray medication (cenegermin) for people who recently lost vision due to a specific type of optic nerve damage (NAION). The goal is to see if it can help restore sight when started within two weeks of vision loss.

Los Angeles, California
NCT06506305Not yet recruiting· Phase 1
Study of fb1001 for recent optic nerve damage

This early-stage study tests an investigational drug called FB1001 for people who have recently experienced a type of sudden vision loss from either acute angle-closure glaucoma or a stroke-like event in the optic nerve (NAION). The treatment aims to protect the optic nerve and potentially preserve your remaining vision.

Shanghai
NCT07777861Recruiting· Phase 2
Testing an eye drop for worsening glaucoma

This study tests an eye drop (G01) for people with primary open-angle glaucoma that is getting worse despite current treatments. It aims to see if G01 can safely slow down or stop the progression of glaucoma.

Beijing, Beijing Municipality
NCT05147701Recruiting· Phase 1
Testing stem cell treatment for NAION safety

This Phase 1 study tests whether lab-made stem cells taken from donated umbilical cord are safe for people with NAION. It mainly looks for side effects and safety rather than proving the treatment works.

St John's
NCT07675824Recruiting· Phase 1/Phase 2
New treatment for open-angle glaucoma or high eye pressure

This trial tests an investigational drug called REGN22530 for people with mild to moderate primary open-angle glaucoma or ocular hypertension (high eye pressure). The goal is to see if it can safely lower eye pressure and protect vision.

Deerfield Beach, Florida

Hear when a new Open Angle Glaucoma (OAG) trial opens

We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.